NCT00680485View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

PHASE1TerminatedINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Bacterial InfectionInfections, Bacterial

Interventions

DRUG

GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY